EMERYVILLE, Calif.--(BUSINESS WIRE)--Ansa Biotechnologies, Inc., the trusted partner for complex DNA synthesis, today announced that it is expanding its early access program for its complex DNA synthesis services. More customers around the world will now be able to take advantage of the company’s innovative enzymatic DNA synthesis technology to accelerate innovation in healthcare, life science research, and other industries powered by synthetic DNA.
Today, scientists are limited in the DNA-based projects they can do because it can be difficult or even impossible to synthesize complex sequences using legacy technologies. Scientists are routinely forced to make compromises with sub-optimal sequences, endure lengthy turnaround times, scale back their aspirations, or stop projects entirely.
Ansa’s DNA synthesis services are based on proprietary technology that enables ultra-rapid production of complex DNA sequences that can be challenging to obtain from conventional vendors. Customers have the option to receive DNA sequences up to 600 bp as sequence-perfect clonal DNA, or in a faster, sequence-verified linear dsDNA fragment format. Ansa’s enzymatic approach eliminates the need for harsh chemicals and does not damage the growing DNA molecule as it is made, which allows for the direct and accurate synthesis of sequences that can be hundreds, and potentially thousands, of bases long. Participants in the early access program are taking advantage of these services to develop critical advancements in therapeutics, vaccines, biomanufacturing, agriculture, and more.
Throughout its early access program, Ansa has delivered synthetic DNA sequences that were previously impossible to synthesize, suffered unpredictable and progress-limiting turnaround times, or were challenged by significant shortcomings in quality. A few highlights from the early access program include complex DNA products that allowed customers to:
- Manufacture sequences with strong secondary structures and an extreme range of GC content to advance research related to microbial gene transfer and communities
- Synthesize highly repetitive spider silk genes for the creation of new materials with a wide range of important applications
- Create all constituent DNA parts required to assemble a complete, high-GC bacteriophage genome for the identification and engineering of potential therapeutic agents
- Rapidly produce protein-coding sequences with tandem repeats to accelerate the development of treatments that can help delay the onset of age-related illnesses
“Based on the overwhelming success of our early access program to date, Ansa is now increasing global availability to our complex DNA synthesis services,” said Jason T. Gammack, CEO of Ansa Biotechnologies. “We strive to be a trusted partner to all of our customers by reliably delivering the complex DNA sequences for their most ambitious research projects that might otherwise be constrained by conventional DNA synthesis techniques.”
Ansa is a proud sponsor of the Global Synthetic Biology (SynBioBeta) Conference this week in San Jose, Calif. Meeting attendees will be able to hear from current customers and learn how to participate in the company’s expanded early access program throughout the conference in booth #312. For more information on the company’s presentations, please visit Ansa’s website.
About Ansa Biotechnologies
Ansa Biotechnologies is enabling customers to push the limits of their scientific projects by delivering DNA sequences that can be difficult or even impossible to produce with legacy synthesis techniques. Ansa’s unique services feature the company’s proprietary synthesis technology, which enables ultra-rapid enzymatic production of complex DNA sequences. This novel approach is poised to accelerate innovation across healthcare, life science research, and other industries powered by synthetic DNA. Ansa is headquartered in Emeryville, CA. For more information, visit ansabio.com or follow on X and LinkedIn.
Ansa Biotechnologies and the Ansa Biotechnologies logo are trademarks of Ansa Biotechnologies, Inc.
